Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Imaging CTLA4 Blockade-induced Cell Replication with [18F]FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab. Journal of Nuclear Medicine 2010 (in press).
2. 2010 A phase II clinical trial of nab-paclitaxel in previously-treated and chemotherapy naive patients with metastatic malignant melanoma. Cancer 2010 Jan 1;116(1):155-63..
3. 2010 Differential Sensitivity of Melanoma Cell Lines with BRAF V600E Mutation to the Specific BRAF Inhibitor PLX4032/RG7204. submitted
4. 2010 Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles submitted
5. 2010 MHC-I restricted Melanoma Antigen Specific TCR Engineered Human CD4+ T Cells Are Multifunctional and Help CD8+ Cytolytic T Lymphocyte Expansion, in vitro submitted
6. 2010 Modulation of Cell Signaling Networks in Peripheral Blood of Patients with Metastatic Melanoma Treated with the CTLA4 Blocking Monoclonal Antibody Tremelimumab submitted
7. 2010 Comparison of Immune Monitoring Assays to Obtain Combined Quantification and Functional Information on Antigen-specific T Cells. submitted
8. 2010 Immune Rejection in a Humanized Model of Murine Prostate Cancer. Anticancer Research 2010 (in press).
9. 2009 Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma. Clinical Cancer Research 2009; Oct 1; 15 (19): 6267-76.
10. 2009 HMGB1 mediates endogenous TLR2 activation and brain tumor regression James F. Curtin, Matthew R. Edwards, Kathrin S. Michelsen, Kurt M. Kroeger, Marianela Candolfi, Chunyan Liu, Mary C Clark, Moshe Arditi, Begonya Comin-Anduix, Antoni Ribas, Pedro R. Lowenstein, Maria G. Castro.
11. 2009 Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008 Pigment Cell Melanoma Research 2009 Oct; 22 (5): 532-43.
12. 2009 Phase I/II Trial of Tremelimumab (CP-675,206), an Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA4) Monoclonal Antibody, in Patients with Metastatic Melanoma. Journal of Clinical Oncology 2009 Mar 1; 27 (7): 1075-81
13. 2009 Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-dioxygenase in Patients With Melanoma Undergoing CTLA4 Blockade. Clinical Cancer Research 2009 Jan 1; 15 (1): 390-9
14. 2009 Quantitative PET Reporter Gene Imaging of Adoptive Immunotherapy for Melanoma. International Immunology 2009 Feb; 21 (2): 155-65.
15. 2009 The Histone Deacetylase Inhibitor LAQ824 Enhances Antitumor Effects of Antigen Specific Adoptive Cell Transfer Therapy Cancer Research 2009 Nov 15; 69 (22): 8693-9.
16. 2009 Heath. Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific Lymphocytes Journal of the American Chemical Society. 2009 Jul 22; 131 (28): 9695-703.
17. 2009 CTLA4 Blockade Increases Th17 Cells in Patients with Metastatic Melanoma. Journal of Translational Medicine 2009 May 20; 7: 35.
18. 2009 Anti-CTLA4 Antibody Clinical Trials in Melanoma Update on Cancer Therapeutics 2009 (in press).
19. 2009 Emerging concepts in biomarker discovery. The US-Japan workshop on immunological molecular markers in oncology. Journal of Translational Medicine 2009 Jun 17; 7 (1): 45.
20. 2009 Role of Anti-CTLA4 mAbs in Treatment of Solid Tumors submitted
21. 2009 Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clinics in Dermatology 2009 Nov-Dec; 27 (6): 603-13.
22. 2009 Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. Journal of Translational Medicine 2009 Jul 29; 7: 68.
23. 2008 Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206). The Oncologist 2008; 13 Suppl 4: 10-5.
24. 2008 Adenovirus MART-1 Engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma Journal of Immunotherapy 2008 Apr;31 (3):294-309.
25. 2008 Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain Cancer Immunology Immunotherapy 2008 Sep; 57 (9):1279-89.
26. 2008 CD4+CD25- T cells transduced to express MHC class I-restricted epitope specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. Journal of Immunology 2008; 181: 1063-70.
27. 2008 T Cell Responses To Survivin In Cancer Patients Undergoing Radiation Therapy Clinical Cancer Research 2008 Aug 1; 14 (15): 4883-90
28. 2008 Detailed Analysis of Immunologic Effects of the Cytotoxic T-lymphocyte Associated Antigen 4-Blocking Monoclonal Antibody CP-675,206 in Peripheral Blood of Patients with Melanoma. Journal of Translational Medicine 2008 May 1; 6: 22.
29. 2008 Journal of Translational Medicine 2008 Dec 23. 6 (1): 81. A systematic approach to biomarker discovery; Preamble to the iSBTc-FDA taskforce on immunotherapy biomarkers.
30. 2008 Targeted Therapies to Improve Tumor Immunotherapy Clinical Cancer Research 2008 Jul 15; 14 (14):4385-91.
31. 2007 Surveillance of the Eye and Vision in Clinical Trials of CP-675,206 for Metastatic Melanoma American Journal of Ophthalmology 2007 Jun; 143 (6): 958-969.
32. 2007 Metastatic melanoma of the kidney presenting with renal vein tumor thrombus Urology 2007 May; 69 (5): 982.
33. 2007 Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Molecular Therapy 2007; 15 (5): 971-980
34. 2007 Therapeutic Cancer Vaccines. Surgical Oncology Clinics of North America 2007 Oct; 16(4):819-31, ix.
35. 2007 Spontaneous and Vaccine Induced AFP-Specific T Cell Phenotypes in Subjects with AFP-positive Hepatocellular Cancer. Cancer Immunology Immunotherapy. 2007; Dec; 56 (12): 1931-43
36. 2007 Tremelimumab, a Cytotoxic T Lymphocyte-Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients With Cancer. The Oncologist 2007 July; 12: 873-883.
37. 2006 Penichet.Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: Implications in immunotherapy and vaccination strategies. Molecular Immunology 2006 Feb; 43(6): 667-76.
38. 2006 Definition of an Immunological Response Using the MHC-Tetramer and ELISPOT Assays Clinical Cancer Research 2006 Jan 1;12 (1): 107-16.
39. 2006 Update on Immunotherapy for Melanoma Journal of the National Comprehensive Cancer Network. 2006 Aug; 4(7): 687-694.
40. 2006 CTLA-4 blocking monoclonal antibodies in the treatment of metastatic melanoma Oncologia (Madrid), 2006, 29 (S1): 93-97
41. 2006 Overcoming Tumor Resistance to Immunotherapy. Cancer Therapy 2006; 4: 13-26
42. 2006 NK and CD4 cells collaborate to reject melanoma metastasis in the brain. Journal of Immunology 2006 Dec 15; 177 (12): 8448-55.
43. 2006 A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients With Dendritic Cells Pulsed With Four AFP Peptides. Clinical Cancer Research 2006 May 1;12 (9):2817-25.
44. 2006 Immunosensitization of Tumor Cells to Dendritic Cell-Activated Innate Responses with the Proteasome Inhibitor Bortezomib. Journal of Immunology 2006 176(8):4757-65.
45. 2005 Antitumor Activity and Anti-Self Responses after CTLA-4 Blockade with the Monoclonal Antibody CP-675,206 Journal of Clinical Oncology 2005 Dec 10; 23 (35): 8968-77.
46. 2005 Broad Antitumor Protection by Dendritic Cells Administered to CD8aKO Mice. Cancer Immunology and Immunotherapy 2005 Aug 13: 1-9.
47. 2005 Clinical Trials with Tumor Antigen Genetically Modified Dendritic Cells Seminars in Oncology 2005 Dec; 32 (6): 556-62.
48. 2005 Genetically Modified Dendritic Cells for Cancer Immunotherapy Current Gene Therapy 2005 Dec, pp. 619-628 (10).
49. 2005 Natural Killer Cells Play a Critical Role in the Immune Response Following Immunization with Melanoma-Antigen-Engineered Dendritic Cells Cancer Gene Therapy 2005 Jun; 12 (6): 516-27.
50. 2005 Combined Immunostimulation and Conditional Cytotoxic Gene Therapy Provide Long-term Survival in a Large Glioma Model. Cancer Research 2005 Aug 15; 65 (16): 7194-204.
51. 2004 Ionizing radiation affects hMART-1 melanoma antigen processing and presentation by dendritic cells Journal of Immunology 2004; Aug 15 173(4): 2462-2469.
52. 2004 Surveillance of the Eye and Vision in a Clinical Trial of MART1-Transformed Dendritic Cells for Metastatic Melanoma. Controlled Clinical Trials 2004; Aug 25(4): 400-407.
53. 2004 Enhanced Tumor Responses to Dendritic Cell Vaccines in the Absence of CD8 Positive Cells Journal of Immunology 2004; 172: 4762-4769.
54. 2004 Human Dendritic Cell Maturation by Adenovirus Transduction Enhances Tumor Antigen-Specific T Cell Responses. Journal of Immunotherapy 2004; May-June 27(3): 191-200.
55. 2004 Role of Dendritic Cell Phenotype, Determinant Spreading and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy. Journal of Immunotherapy 2004; Sep-Oct 27 (5): 354-367.
56. 2003 Determinant Spreading and Responses to Peptide-Based Immunotherapy. Trends in Immunology 2003; 24(2): 58-61.
57. 2003 Determinant Spreading Associated with Clinical Response in Dendritic Cell-Based Immunotherapy for Malignant Melanoma Clinical Cancer Research 2003; 3: 998-1008.
58. 2003 T Cell Responses To HLA-A*0201 Immunodominant Peptides Derived From Alpha Fetoprotein in Patients with Hepatocellular Cancer Clinical Cancer Research 2003; 9: 5902-5905.
59. 2003 Biology of Neoplasia Journal of Clinical Oncology 2003; 21: 2415-2432.
60. 2002 Immunosuppressive Effects of Interleukin-12 Co-Expression in Melanoma Antigen Gene-Modified Dendritic Cell Vaccines. Cancer Gene Therapy 2002; 9:875-883
61. 2002 Antitumor Vaccines in Clinical Development Medicina Clinica 2002, 118 (12): 472-476.
62. 2002 Cancer Immunotherapy Using Gene-Modified Dendritic Cells Current Gene Therapy 2002; 2: 57-78.
63. 2002 Immunotherapy of Hepatocellular Carcinoma. Expert Opinion in Biological Therapy 2002; 2 (2): 123-133.
64. 2002 Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Investigation 2002; 20 (5-6):673-85.
65. 2001 Alpha Fetoprotein-Specific Tumor Immunity Induced by Plasmid Prime-Adenovirus Boost Genetic Vaccination Cancer Research 2001; 61: 8782-8786.
66. 2001 Immunogenicity of the Analogues of the Immunodominant Epitope Human Alpha Fetoprotein 542-550. Molecular Immunology 2001; 37: 943-950.
67. 2001 T cell responses to HLA-A2.1-restricted peptide epitopes from alpha fetoprotein. Journal of Immunology 2001; 166: 5300-5308.
68. 2001 CD40 Crosslinking Bypasses the Absolute Requirement for CD4 Cells After Immunization with Gene-Modified Dendritic Cells. Cancer Research 2001; 61: 8787-8793.
69. 2000 Economou. Genetic immunotherapy for cancer. The Oncologist 2000; 5(2): 87-98
70. 2000 Antitumor immunology in the year 2000 and the new immunosuppressive therapy Medicina Clinica 2000 Apr 22, 114 (15): 579-583.
71. 2000 The Shifting Patterns of Metastatic Melanoma. Clinics in Laboratory Medicine 2000; 20: 759-783.
72. 2000 Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell lines. Cancer Investigation 2000; 18(5): 429-35.
73. 2000 Generation of T cell immunity to a murine melanoma using MART-1-engineered dendritic cells Generation of T cell immunity to a murine melanoma using MART-1-engineered dendritic cells
74. 2000 Immune Deviation and Fas-mediated Deletion Limit Antitumor Activity after Multiple Dendritic Cell Vaccinations in Mice Cancer Research 2000; 60(8): 2218-24.
75. 2000 Adenovirus-IL-12-Mediated Tumor Regression in a Murine Hepatocellular Carcinoma Model is Not Dependent on CD1-Restricted Natural Killer-T Cells. Cancer Research 2000; 60 (22): 6457-64.
76. 1999 Economou. Alpha Fetoprotein-Specific Immunotherapy for Hepatocellular Carcinoma Cancer Research 1999; 59: 3064-3067.
77. 1999 Generation of human T cell responses to an HLA-A2.1-restricted peptide epitope from alpha fetoprotein Cancer Research 1999; 59: 3134-3142.
78. 1999 p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Research 1999; 59: 4369-4374.
79. 1999 Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Therapy 1999; 6: 523-536.
80. 1999 Antitumor Protection Using Murine Dendritic Cells Pulsed with Acid-Eluted Peptides from In Vivo Grown Tumors of Different Immunogenicities Anticancer Research 1999; 19: 1165-1170.
81. 1998 Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector Anticancer Research 1998; 18: 1357-1360.
82. 1998 Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. Journal of Immunology 1998; 161: 5607-5613.
83. 1998 Cyclophosphamide, methotrexate and chronic oral tegafur modulated by folinic acid in advanced breast cancer Cancer 1998; 82(5): 878-885.
84. 1997 Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule Acta Oncologica 1997; 36(7): 701-704.
85. 1997 How important is hepatitis C virus (HCV)-infection in persons with acute leukemia? Leukemia Research 1997; 21: 785-788
86. 1997 Two people with solid cancers surviving 20-years after an auto- or twin transplant Bone Marrow Transplantation 1997; 20: 1103-4.
87. 1997 Carboplatin vs cisplatin-based chemotherapy in advanced surgically incurable bladder cancer. Cancer 1997; 80(10): 1966-72.
88. 1997 Feasibility trial of high-dose 7-day continuous infusion ifosfamide given in an outpatient ba Cancer Chemotherapy and Pharmacology 1997; 40: 273-6.
89. 1997 Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin. Clinical Oncology 1997; 9(4): 269-70.
90. 1997 In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2 Human Gene Therapy 1997; 8: 2173-82.
91. 1997 Economou. Genetic immunization to the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells Cancer Research 1997; 57: 2865-9.
92. 1996 p53 and classical prognostic factors for survival in invasive bladder cancer: Analysis of a cohort of patients treated with a neoadjuvant carboplatin-based regimen. Tumori 1996; 82: 550-555.
93. 1996 Preliminary results of a randomized phase II clinical trial comparing M-VAC y M-CAVI in patients with bladder cancer Archivos Espanoles de Urologia 1996; 49:465-472
94. 1996 Five-day course of granulocyte-colony stimulating factor is a feasible and cost-effective strategy to maintain dose intensity in the adjuvant treatment of breast cancer. Journal of Clinical Oncology 1996; 14 (5): 1573-1580.
95. 1996 M-CAVI: A Neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. American Journal of Clinical Oncology 1996; 19: 344-48.
96. 1996 Node-negative breast cancer with p53(-)/Her2-neu(-) status may identify women with very good prognosis Anticancer Research 1996; 16: 1027-1032.
97. 1995 Multicentric Castleman Disease: Current Aspects of Pathogenesis Sangre 1995; 40: 401-406.
98. 1995 Malignant lymphoproliferative diseases in patients seropositive for the human immunodeficiency virus. A study of 40 cases in a single institution in Spain Acta Oncologica 1995; 34:75-82.
99. 1995 Phase II trial of an all-oral regimen of Tegafur and folinic acid in patients with previously treated metastatic breast cancer Cancer 1995; 75: 831-835.
100. 1995 Paciente de 14 aos con masa costal. In J. Garca-Conde editor. Clinical Sessions in Hematology-Oncology Meditor. Madrid, 1995 pp. 241-246.
101. 1994 Presenting clinical characteristics of malignant lymphoproliferative processes in patients seropositive for the acquired immune deficiency virus Anales de Medicina Interna 1994;11:217-223.
102. 1993 Uso clinico de los factores de crecimineto hematopoyeticos (hematopoyetinas). Medicina Clinica 1993; 100: 707-711.
103. 1993 Non Hodgkin Lymphomas Associated to the Acquired Immune Deficiency Syndrome Sangre 1993; 38: 379-384
104. 1992 Carboplatin, Methotrexate, and Vinblastine in patients with bladder cancer ineligible for cisplatin based chemotherapy Cancer 1992; 70: 1974-1979.
105. 1990 What is the role of recombinant colony stimulating factors in bone marrow transplantation? Bone Marrow Transplantation 1990; 6: 79 87.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.